Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary

Acadia Pharmaceuticals

08/05/2025 02:03

ACADIA Pharmaceuticals Inc ACAD.OQ reported quarterly adjusted earnings of 11 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 10 cents.  The mean expectation of nineteen analysts for the quarter was for earnings of 11 cents per share. Wall Street expected results to range from 1 cents to 28 cents per share.

Revenue rose 18.7% to $244.32 million from a year ago; analysts expected $239.34 million.

ACADIA Pharmaceuticals Inc's reported EPS for the quarter was 11 cents​.

The company reported quarterly net income of $18.99 million.

ACADIA Pharmaceuticals Inc shares had fallen by 12.5% this quarter and lost 20.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 237.6% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 7 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $24.00

This summary was machine generated from LSEG data May 8 at 01:03 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
0.11
0.11
Met
Dec. 31 2024
0.22
-0.02
Missed
Sep. 30 2024
0.14
0.20
Beat
Jun. 30 2024
0.18
0.20
Beat